Gibbon ape leukemia virus envelope glycoprotein (GaLV Env)

The Gibbon ape leukemia virus (GaLV) envelope glycoprotein is a class I viral fusion protein that mediates the entry of the GaLV retrovirus into host cells. It is synthesized as a precursor polyprotein that is subsequently cleaved into two functional subunits: the surface (SU) subunit, which is responsible for high-affinity binding to the host cell receptor, and the transmembrane (TM) subunit, which facilitates the fusion of viral and cellular membranes (UniProt: P03395). The specific cellular receptor for GaLV Env is the inorganic phosphate transporter 1 (PiT-1), encoded by the SLC20A1 gene, which is widely expressed across various human tissues, including hematopoietic stem cells and T-lymphocytes (PubMed: 10438816). Because of this broad and efficient entry mechanism, the GaLV glycoprotein is extensively used in biotechnology to pseudotype retroviral and lentiviral vectors for gene therapy, allowing for the effective delivery of therapeutic genes into human cells (PubMed: 11152491). While the virus itself is associated with leukemia and lymphoma in gibbons, the glycoprotein is not a target for standard human pharmacotherapy but is a vital component in the engineering of advanced medicinal products. Safety considerations for its use in humans include monitoring for potential immune reactions against the viral protein and ensuring the genomic stability of the vectors used.

Other names

GaLV-gpEnvelope polyproteinGibbon ape leukemia virus envelope proteinGaLV glycoprotein

The glycoprotein binds to the host cell surface receptor SLC20A1 (PiT-1) via its surface (SU) subunit, which induces conformational changes in the transmembrane (TM) subunit to facilitate fusion between the viral envelope and the host cell membrane (PubMed: 10438816, PubMed: 7685103).